Page 1 of 1

Sexual desire and migraine headache may be linked

A study from researchers at the Wake Forest University School of Medicine suggests that not all headache sufferers avoid sexual activity. In fact, migraine sufferers reported higher levels of sexual desire than those with other types of headaches. " Our study suggests that sexual desire and migra...
Read Article

Better survival seen for early breast cancer patients switched from Tamoxifen to Exemestane

Hormone sensitive postmenopausal early breast cancer patients who switched to Exemestane ( Aromasin ) after 2 to 3 years of Tamoxifen were 17% more likely to be alive and were 25% less likely to have their cancer return than patients who continued on Tamoxifen for a full 5 years of therapy, accordi...
Read Article

AMG 531 increases platelets in patients with immune thrombocytopenic purpura

Interim results from an open-label study have shown that long-term administration ( up to 48 weeks ) of its investigational therapy AMG 531 was generally well-tolerated and stimulated platelet production in patients with immune thrombocytopenic purpura ( ITP ). Overall, 85 percent of patients in ...
Read Article

End-stage renal disease: higher dose formulation of Fosrenol approved to reduce serum phosphorus

The FDA ( U.S. Food and Drug Administration ) has approved a new, higher dose formulation of the chewable non-calcium phosphate binder Fosrenol ( Lanthanum carbonate ). The new, higher dose strengths of 750 mg and 1.0 g will be available in the U.S. by year end. This formulation will help to reduc...
Read Article

Erbitux shows promise in cancer treatment

The results of several clinical studies of Cetuximab ( Erbitux ) have been presented at the American Society of Clinical Oncology ( ASCO ) 41st Annual Meeting. Irinotecan-refractory metastatic colorectal cancer Findings were presented of a randomized Phase II trial conducted by the National...
Read Article

Zometa improves BMD in breast cancer patients receiving adjuvant therapy

Zoledronic Acid ( Zometa ), an intravenous bisphosphonate, was shown to inhibit aromatase inhibitor-induced bone loss in postmenopausal women treated with Letrozole ( Femara ) in the adjuvant breast cancer setting. Final data of the primary endpoint of 12-month bone mineral density ( BMD ) demons...
Read Article

Non-Hodgkin's lymphoma, earlier use of Bexxar may improve treatment outcomes

Treatment outcomes associated with the Bexxar therapeutic regimen ( Tositumomab and Iodine I 131 Tositumomab ) in non-Hodgkin's lymphoma patients were significantly improved when Bexxar was administered earlier in the treatment sequence. The review compared the treatment responses of 1,177 patien...
Read Article

Early breast cancer, Femara prolongs disease-free survival

The treatment with Letrozole ( Femara ) of postmenopausal women with early breast cancer prolonged disease-free survival by reducing the risk of recurrence an additional 19% over that offered by Tamoxifen ( Nolvadex ) when used as initial treatment after surgery, according to data from the Breast In...
Read Article